National Cancer Institute (NCI)
This phase II trial compares mosunetuzumab to the usual treatment (rituximab) for improving survival in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Rituximab and mosunetuzumab are monoclonal antibodies. They bind to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab may be more effective at extending survival in patients with NLPHL than the usual approach with rituximab.
PRIMARY OBJECTIVE: I. To compare the progression-free survival (PFS) of mosunetuzumab versus rituximab in NLPHL patients. SECONDARY OBJECTIVES: I. To compare the safety and antitumor activity of NLPHL patients treated with mosunetuzumab versus rituximab. II. To evaluate the molecular effects of mosunetuzumab and rituximab on tumor cells and the immune response and identify biomarkers of response or resistance with ribonucleic acid sequencing (RNAseq), whole exome sequencing (WES), immunohistochemistry (IHC) CD20, PD-1, PD-L1, PD-L2. III. To evaluate tumor microenvironment and peripheral i…
Inclusion Criteria: * Histopathologically confirmed diagnosis of NLPHL as confirmed by local pathologist's expert review. * Untreated NLPHL: stage IB to IV according to Cotswolds. The proportion of patients with stages I or II treated with consolidative radiotherapy will be capped at 40%. * Previously treated NLPHL, any stage. * According to the treating physician, the patient should not be observed and needs therapy, notably because of B-symptoms (unexplained fever \[temperature \> 38 degrees Celsius (\> 100.4 degrees Fahrenheit)\], weight loss \[unexplained loss of \> 10 percent of b…
Undergo tissue biopsy
Undergo blood sample collection
Undergo bone marrow biopsy
Undergo PET/CT
Receive FDG
Given SC
Undergo PET/CT
Given IV
Given SC